ArticleLeukemia2022

Idelalisib activates AKT via increased recruitment of PI3Kδ/PI3Kβ to BCR signalosome while reducing PDK1 in post-therapy CLL cells.

Murali K Mamidi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.